Q1 Results beat, guidance hike push Lundbeck up 12.7%

H Lundbeck A/S

14/05/2025 08:16

** Shares in H Lundbeck HLUNa.CO rise 12.7% after the Danish pharmaceutical company reported Q1 results above estimates and raised FY revenue and EBITDA guidance

** Lundbeck's Q1 adjusted EBITDA reached 2.17 billion Danish crowns ($325.45 million), above the 1.79 billion crowns in a company-compiled consensus

** "A strong quarter, with a big beat compared to expectations. But also a quarter that we should not extrapolate too much into the rest of the year, for example due to stock restocking in Rexulti and R&D costs ramping up," says Morten Larsen from ABG Sundal Collier

** Lundbeck also raised its 2025 outlook, driven by strong demand of strategic brands in general, particularly the migraine drug Vyepti and depression drug Rexulti, says Jefferies in a note

** But the broker adds that the guidance does not assume impact from any major healthcare reforms or legislative changes, which implies U.S. tariffs and most favoured nation pricing

** The stock was up 12.7% at 0703 GMT, on track for its best day ever if gains hold

($1 = 6.6677 Danish crowns)

 (Reporting by Vera Dvorakova)

 ((vera.dvorakova@thomsonreuters.com))